The firm has positioned the region as a cornerstone of its Ambition 2030 strategy. With 43% of the worlds pipeline now originating from Asia, Cynthia Wang, head of BD Asia at Servier, spoke to BioXconomy ahead of Asia Bio Partnering Forum in Singapore about how the company is not merely expanding geographically – it is reimagining how global pharmaceutical innovation happens.
In an increasingly interconnected biopharma ecosystem, Servier's approach offers a compelling case study of how established multinational pharmaceutical companies can successfully partner with Asia's rapidly maturing biotech sector. The company's strategy goes beyond traditional licensing deals and aims to embrace Asia as an innovation hub, a productivity engine, and a global capability center.
"We should avoid over-simplifying the evolution as 'me-too to first-in-class,'" noted Wang. "In reality, the region now includes a broad spectrum of innovation, from highly competitive best-in-class approaches to emerging first-in-class science."
Related:Sanofi and Servier execs talk oncology: Pitches, Europe's position, and China's advantage
This maturation is evident across multiple dimensions. Asian researchers now contribute 18% of publications in top-tier scientific journals, while 31% of Phase III clinical trials globally involve Asian participation. Perhaps most tellingly, Wang referenced that 15% of US Food and Drug Administration (FDA) approvals in 2025 originated from Asian innovation.
The quality of science emerging from the region has evolved dramatically. China has established leadership in next-generation oncology modalities, including antibody drug conjugates (ADCs) and multi-specific antibodies, with designs and novel linker-payload technologies. Meanwhile, Japan excels in precision science, South Korea advances cutting-edge modalities, and Australia provides a robust clinical research ecosystem for early-stage development.
A partnership-first approach
Servier's Asia strategy places emphasis on genuine partnership rather than transactional licensing. The company's governance structure as a non-profit foundation – rather than a publicly traded corporation – enables long-term thinking that aligns with the ambitions of Asian innovators seeking to maximize their assets' global potential.
"For Asian biotech companies with global ambitions, the right partner needs to bring more than geographic reach," Wang said. "They need scientific understanding, development experience, regulatory expertise and a genuine commitment to the long-term value of the innovation."
This philosophy has translated into concrete action. Since 2024, Servier has established seven partnerships to build its oncology and neurology pipeline. This includes two significant collaborations with Chinese innovators. The partnership with BioNova provides access to BN104, a menin inhibitor for acute leukemia that strengthens Servier's Isocitrate Dehydrogenase (IDH) franchise. Meanwhile, its collaboration with Insilico Medicine represents confidence on artificial intelligence (AI)-driven drug discovery.
Related:Servier to buy Edgewise’s muscular dystrophy biz in $2.65bn deal
Servier's experience reveals important differences in how Asian biotechs approach partnerships compared to their Western counterparts. Asian partners increasingly favor flexible, creative deal structures – including multi-asset collaborations, platform-based partnerships, and co-development arrangements. They often seek to retain regional rights while accessing global development and commercialization capabilities for other markets.
"Partnership models in Asia are becoming more sophisticated, flexible, and globally oriented," Wang told us. Servier has adapted by offering more comprehensive strategic collaboration models that go beyond traditional licensing, including risk-sharing across development and commercialization phases.
The speed advantage
One of Asia's most valuable contributions to Servier's global operations is what Wang called "Asia speed" – the region's integrated R&D ecosystem that enables rapid patient recruitment and accelerated clinical development. Servier makes use of this agility for signal-seeking studies, running fast, small-scale trials to identify promising signals for indication expansion that inform global development strategy.
Related:Servier to acquire Day One Biopharmaceuticals in $2.5bn rare cancer deal
China's scale and translational innovation capabilities, combined with AI-powered drug discovery tools, allow Servier to feed its global pipeline more efficiently. The company maintains local teams across BD, external innovation, and clinical operations to scout and identify high-quality assets aligned with its global roadmaps.
Despite Asia's remarkable progress, Wang acknowledged that challenges remain in achieving full parity with Western innovation ecosystems. These gaps represent "the natural next stage of ecosystem maturity" rather than fundamental limitations.
Wang outlined some key areas for continued development. This includes global clinical development expertise in designing and executing large-scale multi-regional clinical trials, sophisticated regulatory strategies for simultaneous approvals across major markets, comprehensive global intellectual property strategies, and robust commercialization and market access capabilities.
“From a broader perspective, there is the need for robust and long-term investment in high-risk basic research and increasingly maturing ecosystem to foster the industry development,” she said.
However, these gaps are closing rapidly. Asian biotechs are becoming increasingly well-funded and sophisticated, with growing capabilities in clinical development, regulatory affairs, and commercialization. This evolution is prompting some companies to pursue global development independently rather than out-licensing.
Servier views this trend not as a threat but as an opportunity to evolve its value proposition. The company is offering more comprehensive strategic collaboration models, including co-development and co-commercialization arrangements.
Looking toward 2030
Rather than fixating on specific pipeline percentage targets, Wang emphasized that success should be measured by the quality of partnerships, the strength of scientific collaboration, and ultimately the impact created for patients globally.
She noted how there is “high alignment between Servier's focus areas – oncology and rare neurology – and Asian innovation” and said they will be focusing on “fostering future collaborations” by utilizing a “local radar to scout and identify high-quality assets aligned with global roadmaps.”
Servier's Asia strategy reflects a broader truth about modern pharmaceutical innovation: the future could be shaped by collaboration across regions, not competition between them. As Asian innovation continues to mature – moving through what some call "Innovation 3.0" – the distinction between "Asian" and "Western" innovation could potentially become meaningless.
What matters is scientific quality, patient impact, and the ability to navigate complex global development and commercialization pathways.
Quotes have been lightly edited for clarity.